The stakes are far higher than cognitive inconvenience alone. A recent meta-analysis of 27 studies encompassing 39,412 patients found that cognitive impairment after stroke was associated with a 59 percent increased risk of recurrent stroke and a twofold increase in mortality. Left untreated, roughly one-third of patients with PSCI progress to severe dementia or disability. The clinical picture spans a spectrum from mild deficits in attention, memory, visuospatial ability, language, and executive function to full post-stroke dementia, often accompanied by psychiatric and behavioral disturbances that erode a patient’s capacity to work, socialize, and live independently. Because these deficits typically persist beyond the acute phase and are formally reassessed at three to six months, with persistence at six months serving as a key diagnostic benchmark, the window for early intervention is narrow and precious.

Current clinical evaluation relies heavily on neuropsychological screening, most commonly the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The 2023 American Heart Association scientific statement on PSCI clearly recommends simple cognitive screening for all stroke patients, with an initial assessment during the acute phase or before discharge and a follow-up at three to six months. The MMSE, while simple to administer, is limited by sensitivity to age and education effects, whereas the MoCA demonstrates superior reliability, validity, and sensitivity. Complementing these direct assessments, informant-based tools such as the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) prove invaluable when patients cannot be reliably tested due to severe motor deficits, aphasia, or reduced consciousness. At the three- to six-month follow-up, the IQCODE achieves a sensitivity of 81 percent and a specificity of 83 percent, comparable to the MoCA, and because it is less influenced by educational level or language barriers, combining the two instruments yields a more accurate and culturally robust identification of PSCI.

Beyond behavioral testing, blood and cerebrospinal fluid biomarkers are emerging as early predictors. Brain-derived neurotrophic factor, protein S100β, soluble intercellular adhesion molecule-1, oxidized low-density lipoprotein, and soluble CD40 ligand all show significant value for early prediction in patients not receiving thrombolytic therapy. Inflammatory markers, including C-reactive protein, erythrocyte sedimentation rate, interleukins, and tumor necrosis factor-α, add further predictive power and hint that anti-inflammatory interventions might one day protect cognition. Genetics compounds the risk: the apolipoprotein E4 (APOE4) allele, long known as a strong risk factor for Alzheimer’s disease, has been identified as an independent risk factor for PSCI in acute ischemic stroke patients. APOE4 accelerates amyloid-β accumulation, promotes tau aggregation, drives neuroinflammation, and alters regional glucose metabolism as measured by FDG-PET, while carriers also exhibit elevated plasma levels of TNFα and interleukin-6, linking vascular and neurodegenerative pathology in a single molecular thread.

Yet it is neuroimaging that has undergone the most dramatic transformation, evolving from simple anatomical localization to a multimodal assessment system that integrates macrostructural, microstructural connectivity, and molecular metabolic information. Where a stroke infarct lands matters enormously. A pooled analysis of individual patient data from 12 acute ischemic stroke cohorts found that infarcts in the left frontotemporal lobe, left thalamus, and right parietal lobe are strongly associated with PSCI, whereas infarcts in the right occipital lobe, brainstem, and cerebellum carry lower risk. Language and verbal memory impairment lateralize predominantly to the left hemisphere, while visuospatial deficits track right parietal damage, consistent with the brain’s asymmetric organization of cognitive functions. Infarct volume adds a second dimension: multivariate analysis indicates that volumes of 0.054 milliliters or greater constitute an independent risk factor, and larger lesions correlate with increased likelihood of involving strategically important regions, meaning location and volume synergistically shape cognitive outcomes.

Cerebral atrophy provides another powerful signal. Medial temporal lobe atrophy, in particular, has attracted intense research attention because prolonged hypoperfusion may drive hippocampal shrinkage and the deposition of tau protein and amyloid precursor protein. A systematic analysis concluded that overall atrophy and medial temporal lobe atrophy are the most consistent predictors of cognitive impairment after stroke, and intriguingly, the timing matters: in the acute and subacute phases, cortical atrophy and white matter lesions do not correlate with PSCI, but by the chronic phase, patients with more severe cortical atrophy show higher overall impairment, with memory and attention deficits more likely to persist. Incorporating the medial temporal lobe atrophy scale into routine stroke MRI evaluation could alert clinicians to looming decline long before symptoms become disabling.

Cerebral small vessel disease (CSVD) represents perhaps the most intricate imaging frontier. White matter lesions, visible as high signal on T2-weighted imaging, arise from chronic small vessel hardening that causes demyelination and gliosis, progressively destabilizing the neural fiber pathways that connect brain regions. In a three-year follow-up of 639 patients with white matter lesions, 90 progressed to dementia and 147 to cognitive dysfunction without dementia. Cerebral microbleeds, whose anatomical distribution varies with underlying etiology, lobar in cerebral amyloid angiopathy versus deep in hypertensive arteriolosclerosis, correlate negatively with cognitive function, and strictly lobar microbleeds or cortical superficial siderosis signal more than a fourfold increase in the odds of amyloid deposition. Perivascular spaces, the interstitial fluid channels that form part of the brain’s glymphatic clearance system, accumulate with age and vascular disease, and higher burden in the centrum semiovale is linked to elevated risk of mild cognitive impairment. Lacunar infarcts, the hallmark of CSVD, damage cognition through both strategic location, such as disruption of the anterior thalamic nuclei within the Papez circuit, and cumulative burden, the so-called lacunar state that dismantles fronto-subcortical networks governing executive function and processing speed. Critically, these markers rarely act alone: the total CSVD score, which integrates white matter hyperintensities, lacunes, microbleeds, and perivascular spaces into a pragmatic 0-to-4 scale, independently predicts poorer global cognition, and scores above 2 forecast long-term cognitive decline and incident dementia.

Cerebral perfusion adds a dynamic layer to this static picture. Chronic hypoperfusion after stroke reduces neuronal excitability and metabolic rate, and even slight impairment of cerebral blood flow regulation can significantly affect brain function. Perfusion deficits in the temporal and frontal lobes, hippocampus, and thalamus correlate with the degree of cognitive dysfunction, and the ischemic penumbra volume, the hypoperfusion intensity ratio, and collateral circulation status all shape final infarct volume and, indirectly, cognitive trajectory. In patients with asymptomatic middle cerebral artery stenosis, poor collateral circulation is frequently comorbid with cognitive domain impairments, whereas good collaterals confer relative protection. A 12-year longitudinal study further revealed that reduced cerebral blood flow is associated with progression of brain atrophy, cementing perfusion as a driver of neurodegeneration rather than a mere bystander.

The most exciting advances, however, lie in multimodal and computational imaging. Diffusion tensor imaging captures damage to white matter tract integrity, while the DTI Analysis along the Perivascular Space (DTI-ALPS) index offers a rapid, contrast-free, noninvasive window into glymphatic system function, the brain’s waste-clearance machinery. Studies show the ALPS index on the lesion side is significantly reduced in ischemic stroke patients, most pronounced in the acute phase with partial recovery over weeks to months, providing a reliable reference for distinguishing early cognitive impairment and predicting unfavorable six-month outcomes. Functional MRI reveals that brain networks in PSCI patients shift toward a suboptimal state with incomplete compensation centered on the frontoparietal network, while combined ASL-fMRI analysis demonstrates altered neurovascular coupling correlated with cognitive scores and white matter lesion burden. Functional near-infrared spectroscopy, portable and motion-robust, detects significantly reduced activation in the left dorsolateral prefrontal cortex of PSCI patients, and its centroid values serve as sensitive severity indicators. Meanwhile, deep learning is automating the entire pipeline: U-Net architectures segment white matter hyperintensities from FLAIR images with high accuracy across multi-center datasets, 3D U-Net models detect microbleeds with performance comparable to expert raters, and interpretable 3D frameworks grade enlarged perivascular spaces in acute stroke cohorts, minimizing inter-rater variability and embedding total CSVD burden scores directly into clinical workflows.

Treatment remains multifaceted rather than curative, anchored in aggressive control of vascular risk factors such as hypertension, diabetes, and hyperlipidemia. No drugs are specifically approved for PSCI, so clinicians borrow from Alzheimer’s protocols, deploying cholinesterase inhibitors like donepezil, calcium antagonists such as nimodipine, and the NMDA receptor antagonist memantine, with traditional Chinese medicines showing promise in regional cohorts that await large-scale international validation. Non-pharmacological approaches, including acupuncture, hyperbaric oxygen therapy, repetitive transcranial magnetic stimulation, and computer-assisted cognitive rehabilitation, are gaining recognition for safety and patient compliance. The review’s authors argue that the next frontier demands longitudinal, multi-timepoint imaging studies at baseline, 3, 6, 12, and 24 months to distinguish individual patterns of cognitive resilience from accelerated decline, and to unravel how acute vascular injury interacts with pre-existing amyloid and tau pathology. As imaging, fluid biomarkers, and artificial intelligence converge, the prospect of dynamic risk stratification and personalized secondary prevention is moving from aspiration toward clinical reality, offering stroke survivors a fighting chance to keep the self they thought they had lost.

Subject of Research: Neuroimaging biomarkers and multimodal imaging advances for post-stroke cognitive impairment

Article Title: Imaging research, diagnosis, and treatment advances of post-stroke cognitive impairment

Article References: Huang, M., Jia, Q., Ouyang, Y., Feng, X., & Ju, R. (2026). Imaging research, diagnosis, and treatment advances of post-stroke cognitive impairment. Frontiers in Neuroimaging, 5, Article 1691870. https://doi.org/10.3389/fnimg.2026.1691870

Image Credits: AI Generated

DOI: 10.3389/fnimg.2026.1691870

Keywords: post-stroke cognitive impairment, neuroimaging, cerebral small vessel disease, stroke, MRI, DTI-ALPS, biomarkers, dementia, perfusion imaging, artificial intelligence, Imaging, research